{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:15:50Z","timestamp":1792451750511,"version":"4.5.0"},"reference-count":60,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Folate receptor alpha (FR\u03b1), commonly expressed in epithelial ovarian cancers, is a clinically actionable biomarker following approval of the antibody\u2013drug conjugate mirvetuximab soravtansine (MIRV). Pivotal trials showed that high FR\u03b1 expression predicts MIRV benefit, creating the need for standardized testing to ensure timely, equitable access. Methods: To address the need for guidance on FR\u03b1 testing, the Society of Gynecologic Oncology of Canada convened a multidisciplinary Expert Panel to review the evidence and integrate Canadian clinical, pathology, laboratory, and patient perspectives. Consensus recommendations were developed through structured evidence review, expert discussion, iterative revision, and patient partner input. Results: The panel issued recommendations on the clinical role and timing of FR\u03b1 testing, tissue requirements, assay selection and validation, interpretation and reporting standards, laboratory quality assurance, reimbursement, and equitable access. It is recommended that FR\u03b1 testing be available to all patients with epithelial ovarian cancer, with results available no later than platinum-resistant disease, using a validated assay, preferably the Ventana FOLR1 RxDx assay or an appropriately validated laboratory-developed test. Standardized synoptic reporting, participation in external quality assurance programs, and clear patient communication were deemed essential. Conclusions: These recommendations aim to promote integrated, equitable, standardized FR\u03b1 testing across Canada and support timely identification of patients eligible for FR\u03b1-directed therapy, clinical trial enrollment, and future biomarker-driven treatment strategies.<\/jats:p>","DOI":"10.3390\/curroncol33060330","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:11:01Z","timestamp":1780333861000},"page":"330","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor \u03b1 Testing in Ovarian Cancer"],"prefix":"10.3390","volume":"33","author":[{"given":"Kim","family":"Ma","sequence":"first","affiliation":[{"name":"Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montr\u00e9al, QC H3T 1E2, Canada"},{"name":"Faculty of Medicine and Health Sciences, McGill University, Montr\u00e9al, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8739-3879","authenticated-orcid":false,"given":"Basile","family":"Tessier-Cloutier","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, McGill University, Montr\u00e9al, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6345-4910","authenticated-orcid":false,"given":"Alon D.","family":"Altman","sequence":"additional","affiliation":[{"name":"Max Rady College of Medicine, Obstetrics, Gynecology and Reproductive Sciences, WN50014\u2014Women\u2019s Hospital, University of Manitoba, Winnipeg, MB R3A 1R9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Carey","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Vancouver Coastal Health; Department of Obstetrics and Gynecology, Faculty of Medicine, University of British Columbia, Vancouver, BC V6H 3N1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josee-Lyne","family":"Ethier","sequence":"additional","affiliation":[{"name":"Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie","family":"Lau","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montr\u00e9al, QC H3T 1E2, Canada"},{"name":"Segal Cancer Centre, Sir Mortimer B. Davis Institute of Medical Research, McGill University, Montr\u00e9al, QC H3T 1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Han","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G 1C9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hopkins","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Saskatoon Cancer Centre, Saskatoon, SK S7N 5B8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Kieser","sequence":"additional","affiliation":[{"name":"Division of Gynaecologic Oncology, Dalhousie University, Halifax, NS B3H 1V7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aalok","family":"Kumar","sequence":"additional","affiliation":[{"name":"BC Cancer-Surrey, University of British Columbia, Vancouver, BC V3V 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-7595","authenticated-orcid":false,"given":"Shuk On Annie","family":"Leung","sequence":"additional","affiliation":[{"name":"McGill University Health Centre, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M. V.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, McMaster University, Hamilton, ON L8S 4K1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"MacKay","sequence":"additional","affiliation":[{"name":"Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3210-0682","authenticated-orcid":false,"given":"Jacob","family":"McGee","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, London Health Sciences Centre and Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Salman","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, London Health Sciences Centre and Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8061-375X","authenticated-orcid":false,"given":"Shannon","family":"Salvador","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montr\u00e9al, QC H3T 1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cidalia","family":"Sluce","sequence":"additional","affiliation":[{"name":"Society of Gynecologic Oncology of Canada, Ottawa, ON K1H 8K3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2581-3209","authenticated-orcid":false,"given":"Luiza","family":"Tatar","sequence":"additional","affiliation":[{"name":"McGill University Health Centre, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9715-4273","authenticated-orcid":false,"given":"Alicia A.","family":"Tone","sequence":"additional","affiliation":[{"name":"Ovarian Cancer Canada, Toronto, ON M2P 2A9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tinker","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Vancouver Coastal Health; Department of Obstetrics and Gynecology, Faculty of Medicine, University of British Columbia, Vancouver, BC V6H 3N1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3152-0765","authenticated-orcid":false,"given":"Elizabeth","family":"Tremblay","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM), Montreal, QC H2X 0A9, Canada"},{"name":"D\u00e9partement d\u2019obst\u00e9trique et gyn\u00e9cologie, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H3T 1J4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"Veneziani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Vicus","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University of Toronto, Toronto, ON M5G 1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Welch","sequence":"additional","affiliation":[{"name":"Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2847-9856","authenticated-orcid":false,"given":"Sharon","family":"Windsor Harker","sequence":"additional","affiliation":[{"name":"Windsor Medical Communications, Inc., Hamilton, ON L8N 1Z6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7595-0313","authenticated-orcid":false,"given":"Melica Nourmoussavi","family":"Brodeur","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montr\u00e9al, QC H3T 1E2, Canada"},{"name":"Faculty of Medicine and Health Sciences, McGill University, Montr\u00e9al, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"ref_1","first-page":"284","article-title":"Ovarian Cancer Statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lisio, M.A., Fu, L., Goyeneche, A., Gao, Z.H., and Telleria, C. (2019). High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040952"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.annonc.2021.07.004","article-title":"Updated Treatment Recommendations for Newly Diagnosed Epithelial Ovarian Carcinoma from the ESMO Clinical Practice Guidelines","volume":"32","author":"Colombo","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1359-6446(00)01594-4","article-title":"Folate-Mediated Targeting: From Diagnostics to Drug and Gene Delivery","volume":"6","author":"Leamon","year":"2001","journal-title":"Drug Discov. Today"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-007-9048-0","article-title":"The Folate Receptor: What Does It Promise in Tissue-Targeted Therapeutics?","volume":"26","author":"Salazar","year":"2007","journal-title":"Cancer Metastasis Rev."},{"key":"ref_6","first-page":"4989","article-title":"A Current Review of Folate Receptor Alpha as a Potential Tumor Target in Non-Small-Cell Lung Cancer","volume":"9","author":"Shi","year":"2015","journal-title":"Drug Des. Devel Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"17442","DOI":"10.18632\/oncotarget.7856","article-title":"Concordance of Folate Receptor-Alpha Expression between Biopsy, Primary Tumor and Metastasis in Breast Cancer and Lung Cancer Patients","volume":"7","author":"Boogerd","year":"2016","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ygyno.2007.11.020","article-title":"Folate Receptor Alpha as a Tumor Target in Epithelial Ovarian Cancer","volume":"108","author":"Kalli","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F","article-title":"Overexpression of Folate Binding Protein in Ovarian Cancers","volume":"74","author":"Toffoli","year":"1997","journal-title":"Int. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/bjc.2014.567","article-title":"Evidence for a Time-Dependent Association between FOLR1 Expression and Survival from Ovarian Carcinoma: Implications for Clinical Testing. An Ovarian Tumour Tissue Analysis Consortium Study","volume":"111","author":"Kobel","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","article-title":"IMGN853, a Folate Receptor-Alpha (FRalpha)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRalpha-Expressing Tumors","volume":"14","author":"Ab","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.34753","article-title":"Chemotherapy Response in Low-Grade Serous Ovarian Carcinoma at a Comprehensive Cancer Center: Readdressing the Roles of Platinum and Cytotoxic Therapies","volume":"129","author":"Kahn","year":"2023","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/cas.14898","article-title":"Antibody-Drug Conjugate MORAb-202 Exhibits Long-Lasting Antitumor Efficacy in TNBC PDx Models","volume":"112","author":"Furuuchi","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","article-title":"Characterization of Folate Receptor Alpha (FRalpha) Expression in Archival Tumor and Biopsy Samples from Relapsed Epithelial Ovarian Cancer Patients: A Phase I Expansion Study of the FRalpha-Targeting Antibody-Drug Conjugate Mirvetuximab Soravtansine","volume":"147","author":"Martin","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/1078-0432.CCR-24-3128","article-title":"Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant\/Refractory High-Grade Ovarian Cancer (NCI Trial)","volume":"31","author":"Alqaisi","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1200\/JCO.2024.42.16_suppl.5580","article-title":"Phase 3 MIRASOL (GOG 3045\/ENGOT-Ov55) Trial: Mirvetuximab Soravtansine (MIRV) vs. Investigator\u2019s Choice Chemotherapy (ICC) in Older Patients with Platinum-Resistant Ovarian Cancer (PROC) and High Folate Receptor-Alpha (FR\u03b1) Expression","volume":"42","author":"Bello","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_18","unstructured":"U.S. Food and Drug Administration (2025, December 05). FDA Approves Mirvetuximab Soravtansine-Gynx for FR\u03b1 Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant-epithelial-ovarian."},{"key":"ref_19","unstructured":"Pelosci, A. (2025, December 03). Health Canada Approves Mirvetuximab Soravtansine in FR\u03b1+ Ovarian Cancer | CancerNetwork. Available online: https:\/\/www.cancernetwork.com\/view\/health-canada-approves-mirvetuximab-soravtansine-in-fr-ovarian-cancer."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/1535-7163.MCT-22-0322","article-title":"Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers","volume":"22","author":"Li","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Oaknin, A., Fari\u00f1as-Madrid, L., Garc\u00eda-Duran, C., Martin, L.P., O\u2019Malley, D.M., Schilder, R.J., Uyar, D., Moroney, J.W., Diaz, J.P., and Spira, A.I. (2025, December 05). Luveltamab Tazevibulin (STRO-002), an Anti-Folate Receptor Alpha Antibody Drug Conjugate, Safety and Efficacy in a Broad Distribution of FOLR\u03b1 Expression in Patients with Recurrent Epithelial Ovarian Cancer: Update of STRO-002-GM1 Phase 1 Dose Expansion Cohort. Available online: https:\/\/www.sutrobio.com\/wp-content\/uploads\/2024\/04\/Sutro_-ASCO-2023-FINAL-Presentation.pdf.","DOI":"10.1200\/JCO.2023.41.16_suppl.5508"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1158\/1078-0432.CCR-20-4740","article-title":"First-in-Human Phase 1 Study of MORAb-202, an Antibody\u2013Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-\u03b1\u2013Positive Advanced Solid Tumors","volume":"27","author":"Shimizu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_23","unstructured":"Bristol-Myers Squibb (2025, December 05). A Phase 2 Open-Label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Versus Investigators Choice Chemotherapy in Women with Platinum-Resistant High-Grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, Available online: https:\/\/clinicaltrials.gov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2113697","DOI":"10.1080\/2162402X.2022.2113697","article-title":"A T-Cell Engaging Bispecific Antibody with a Tumor-Selective Bivalent Folate Receptor Alpha Binding Arm for the Treatment of Ovarian Cancer","volume":"11","author":"Avanzino","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref_25","unstructured":"University of Pennsylvania (2025, December 05). MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03585764?cond=%22Primary%20Peritoneal%20Carcinoma%22&intr=%22fludarabine%20phosphate%22&viewType=Table&rank=2."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1479-5876-10-157","article-title":"A Phase I Clinical Trial of Adoptive Transfer of Folate Receptor-Alpha Redirected Autologous T Cells for Recurrent Ovarian Cancer","volume":"10","author":"Kandalaft","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1158\/1078-0432.CCR-15-2640","article-title":"A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer","volume":"22","author":"Hoogstins","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_28","unstructured":"U.S. Food and Drug Administration (2026, February 18). FDA D.I.S.C.O. Burst Edition: FDA Approvals of Cytalux (Pafolacianine) for Identifying Malignant Ovarian Cancer Lesions and Darzalex Faspro (Daratumumab + Hyaluronidase-Fihj), Kyprolis (Carfilzomib) and Dexamethasone for Multiple Myeloma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approvals-cytalux-pafolacianine-identifying-malignant-ovarian-cancer."},{"key":"ref_29","unstructured":"Todd, J. (2026, February 18). On Target Laboratories Announces Expanded Indication of CYTALUX\u00ae (Pafolacianine) Injection for Detection of Lung Cancer During Surgery. Available online: http:\/\/jnjinnovation.com\/news\/press-releases\/on-target-laboratories-announces-expanded-indication-of-cytalux-pafolacianine-injection-for-detection-of-lung-cancer-during-surgery."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ygyno.2023.12.010","article-title":"Germline and Somatic Testing for Ovarian Cancer: An SGO Clinical Practice Statement","volume":"181","author":"Gressel","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.20.02785","article-title":"Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019","volume":"39","author":"Kurian","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13048-021-00908-8","article-title":"The Prognostic Factor for Recurrence in Advanced-Stage High-Grade Serous Ovarian Cancer after Complete Clinical Remission: A Nested Case-Control Study","volume":"14","author":"Wang","year":"2021","journal-title":"J. Ovarian Res."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Adzibolosu, N., Alvero, A.B., Ali-Fehmi, R., Gogoi, R., Corey, L., Tedja, R., Chehade, H., Gogoi, V., Morris, R., and Anderson, M. (2023). Immunological Modifications Following Chemotherapy Are Associated with Delayed Recurrence of Ovarian Cancer. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1204148"},{"key":"ref_34","unstructured":"U.S. Food and Drug Administration (2025, December 05). FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-Gynx for FR\u03b1 Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant."},{"key":"ref_35","unstructured":"ELAHERE\u00ae (2025). Mirvetuximab Soravtansine Product Monograph 2025, AbbVie Corporation."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2559.2006.02513.x","article-title":"Quantification of Immunohistochemistry--Issues Concerning Methods, Utility and Semiquantitative Assessment II","volume":"49","author":"Taylor","year":"2006","journal-title":"Histopathology"},{"key":"ref_37","unstructured":"Roche Tissue Diagnostics (2025, December 05). VENTANA FOLR1 (FOLR1-2.1) RxDx Assay Interpretation Guide for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Available online: https:\/\/usinfo.roche.com\/rs\/975-FPO-828\/images\/Interpretation%20guide%20FOLR1%20RxDx%20assay%2011.14.22%20BG%20FINAL.pdf."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","article-title":"Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology\/Gynecologic Oncology Group Study","volume":"24","author":"Norquist","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.5858\/arpa.2023-0149-OA","article-title":"Development of an FRalpha Companion Diagnostic Immunohistochemical Assay for Mirvetuximab Soravtansine","volume":"148","author":"James","year":"2024","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_41","unstructured":"Seymour, C. (2025, December 05). FDA Approves First IHC Companion Diagnostic for Mirvetuximab Soravtansine in Ovarian Cancer. Available online: https:\/\/www.onclive.com\/view\/fda-approves-first-ihc-companion-diagnostic-for-mirvetuximab-soravtansine-in-ovarian-cancer."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"LBA5507","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5507","article-title":"Phase III MIRASOL (GOG 3045\/ENGOT-Ov55) Study: Initial Report of Mirvetuximab Soravtansine vs. Investigator\u2019s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression","volume":"41","author":"Moore","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2024.11.011","article-title":"The Efficacy and Safety of Mirvetuximab Soravtansine in FR\u03b1-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase II PICCOLO Trial","volume":"36","author":"Lewin","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"TPS5622","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5622","article-title":"GLORIOSA: A Randomized, Open-Label, Phase 3 Study of Mirvetuximab Soravtansine with Bevacizumab vs. Bevacizumab as Maintenance in Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","volume":"41","author":"Myers","year":"2023","journal-title":"JCO"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1080\/14796694.2024.2372241","article-title":"Maintenance with Mirvetuximab Soravtansine plus Bevacizumab vs Bevacizumab in FR\u03b1-High Platinum-Sensitive Ovarian Cancer","volume":"20","author":"Myers","year":"2024","journal-title":"Future Oncol."},{"key":"ref_46","unstructured":"Biosystems, L. (2025, December 05). Folate Receptor Alpha IHC Primary Antibody, Clone BN3.2 (Data Sheet). Available online: https:\/\/shop.leicabiosystems.com\/us\/ihc-ish\/ihc-primary-antibodies\/pid-folate-receptor-alpha."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/hyb.2007.0512","article-title":"A Novel Monoclonal Antibody for Detection of Folate Receptor Alpha in Paraffin-Embedded Tissues","volume":"26","author":"Smith","year":"2007","journal-title":"Hybridoma"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Scheiter, A., Mattern, S., Gassenmaier, V., Schildhaus, H.-U., Christgen, M., Kreipe, H., Herbst, H., Lambert, B., Sauter, G., and Lennartz, M. (2025). Results of the First Folate Receptor Alpha Testing Trial by the German Quality Assurance Initiative in Pathology (QuIP\u00ae). Cancers, 17.","DOI":"10.3390\/cancers17223703"},{"key":"ref_49","unstructured":"(2025, December 05). College of American Pathologists Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Ovary, Fallopian Tube, or Primary Peritoneum (v1.0.0.0). Available online: https:\/\/documents.cap.org\/protocols\/cap-ovary-biomarker-23protocol-1000.pdf."},{"key":"ref_50","unstructured":"Prahlad, M. (2025, December 05). Uncovering Inequalities in Breast Cancer Immunotherapy Access. Available online: https:\/\/www.uchicagomedicine.org\/forefront\/cancer-articles\/inequalities-in-breast-cancer-immunotherapy-access."},{"key":"ref_51","first-page":"100251","article-title":"The Right to Be Screened: Identifying and Addressing Inequities in Genetic Screening","volume":"11","author":"Swami","year":"2022","journal-title":"Lancet Reg. Health Am."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.3390\/curroncol31030103","article-title":"Barriers and Unequal Access to Timely Molecular Testing Results: Addressing the Inequities in Cancer Care Delays across Canada","volume":"31","author":"Snow","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11606-020-06064-x","article-title":"Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center","volume":"36","author":"Zhou","year":"2021","journal-title":"J. Gen. Intern. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cncr.30621","article-title":"Racial Disparities in BRCA Testing and Cancer Risk Management across a Population-Based Sample of Young Breast Cancer Survivors","volume":"123","author":"Cragun","year":"2017","journal-title":"Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ygyno.2019.03.007","article-title":"Identifying Disparities in Germline and Somatic Testing for Ovarian Cancer","volume":"153","author":"Huang","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3747\/co.22.2599","article-title":"Disparity in Cancer Prevention and Screening in Aboriginal Populations: Recommendations for Action","volume":"22","author":"Ahmed","year":"2015","journal-title":"Curr. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s40615-022-01259-w","article-title":"Residential Locale Is Associated with Disparities in Genetic Testing-Related Outcomes Among BRCA1\/2-Positive Women","volume":"10","author":"Dibble","year":"2023","journal-title":"J. Racial Ethn. Health Disparities"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/COC.0000000000001039","article-title":"Geographic Disparities in Access to Cancer Clinical Trials in Canada","volume":"46","year":"2023","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_59","first-page":"1","article-title":"Comparative Analysis of Public Health Care Systems and Call of Reform in Canada","volume":"8","author":"Wu","year":"2025","journal-title":"Natl. High Sch. J. Sci."},{"key":"ref_60","unstructured":"Yet, A. (2025, December 05). A Review of Precision Medicine Companion Diagnostics in Canada. Available online: https:\/\/survivornet.ca\/wp-content\/uploads\/2021\/01\/A-Review-of-Precision-Medicine-Companion-Diagnostics-in-Canada.pdf."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/330\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:43:09Z","timestamp":1780335789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":60,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["curroncol33060330"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33060330","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}